Curated News
By: NewsRamp Editorial Staff
April 29, 2025
Tonix Pharmaceuticals Presents Positive Data on Immuno-Oncology Candidate at AACR 2025 Annual Meeting
TLDR
- Tonix Pharmaceuticals showcased positive data for TNX-1700 at AACR 2025, positioning itself as a leader in immuno-oncology advancements.
- TNX-1700, a fusion protein version of TFF2, exhibits reduced immunosuppressive neutrophils and enhanced anti-tumor immune responses in gastric cancer models.
- The development of TNX-1700 aims to revolutionize treatments for gastric and colon cancers, offering hope for improved patient outcomes and quality of life.
- Combining TNX-1700 with anti-PD1 therapy shows promising results in enhancing immune responses against tumors, potentially paving the way for more effective cancer treatments.
Impact - Why it Matters
This news matters as it highlights the promising results of TNX-1700 in treating gastric cancer, showing the potential for improved anti-tumor immune responses. The development of innovative therapies targeting the tumor microenvironment is crucial for advancing cancer treatment and improving patient outcomes.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) presented positive data supporting TNX-1700, its lead immuno-oncology candidate, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. Preclinical results showed that a fusion protein version of TFF2 significantly reduced immunosuppressive neutrophils and enhanced anti-tumor immune responses in gastric cancer models, especially when combined with anti-PD1 therapy. Tonix is advancing TNX-1700 under a license from Columbia University as part of its strategy to develop treatments targeting the tumor microenvironment in gastric and colon cancers.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Presents Positive Data on Immuno-Oncology Candidate at AACR 2025 Annual Meeting
